Trial Profile

A Phase 3, Multi-center, Randomized, Double-Blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of Topical Administration of Minocycline Hydrochloride Foam (4%) in the Treatment of Moderate-to-Severe Acne Vulgaris

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 May 2025 Results (n=372) assessing the impact of FMX101 4% treatment for 12 weeks on the inflammation lesion count (ILC), noninflammatory lesion count (nILC) and IGA treatment success rate in Chinese subjects with moderate-to-severe facial Acne Vulgaris (AV), presented in the Journal of the European Academy of Dermatology and Venereology.
26 Sep 2023 Status changed from active, no longer recruiting to completed.
15 Feb 2023 Planned End Date changed from 5 Oct 2022 to 30 Oct 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com